Prof. Ulrike Protzer and Dr. Felix Bohne investigate the results of the blood samples of HCV-infected transplant patients. (Photo: E. Mitterwallner / TUM)
Prof. Ulrike Protzer and Dr. Felix Bohne investigate the results of the blood samples of HCV-infected transplant patients. (Photo: E. Mitterwallner / TUM)
  • Research news

A question of tolerance: Liver transplants in patients with hepatitis CVirus infection supports organ acceptance

Chronic hepatitis C virus infections are among the most common reasons for liver transplants. Because existing viruses also infect the new liver, the immune system is highly active there. Despite this, the new organ is not rejected, as scientists from the Helmholtz Zentrum München and the Technische Universität München (TUM) have now discovered. The long-term stimulation of the innate immune system by the virus actually increases the probability of tolerance.

Over 150 million people throughout the world suffer from chronic infection with the hepatitis C virus (HCV), which causes massive damage to the liver. Advanced liver diseases often necessitate liver transplants. In the new clinical study Dr. Felix Bohne and his colleagues studied together with Prof. Alberto Sánchez-Fueyo from King’s College London 34 hepatitis C patients at the Liver Unit of the University Hospital Clínic de Barcelona who had received new livers.

The researchers had two objectives here: first, they wanted to gain a better understanding of the mechanisms that enable the body’s own immune system to tolerate the new organ despite the HCV infection; second, they were looking for factors that could act as biomarkers for tolerance in the patients.

“If tolerance could be reliably predicted based on certain markers, many patients could stop taking immunosuppressants after a certain period of time,” explains Dr. Felix Bohne, lead scientist of the study. Patients must take these strong drugs after transplants. They suppress the immune system so that the body does not identify the new organ as foreign and reject it. For patients with hepatitis C, this is a particular burden, as they need a stable immune system after the transplant to control their chronic HCV infection.
Markers for tolerance

During the study, the patients stopped taking the immunosuppressants. They were observed for twelve months to see which of them could also tolerate the new organ without the drugs, and which of them did not. The scientists took liver and blood samples from the patients prior to and after the cessation of the drugs. Detailed immunological tests on these patient samples were carried out under the leadership of Prof. Ulrike Protzer of the “Immunmonitoring Platform” at the Institute of Virology. The scientists compared the patients with each other and looked for any differences that arose in tolerant patients only.

And the scientists struck gold: a certain group of genes was very active only in the livers of tolerant patients. The genes in question belonged to the type I interferon system, which targets viruses like HCV as part of the innate immune system. As the results showed, an anti-viral mechanism does actually enable the patients to better tolerate a foreign organ.

Ulrike Protzer provides a possible explanation for this: “When the interferon system is constantly activated as is the case in some chronically-infected patients, it downregulates other immune reactions in order to protect the body. This state could act like a natural immunosuppressant and reduce the rejection of the organ.”

In addition to the genes of the type I interferon system, a second factor was considered as a possible marker. This was discovered by the researchers in a previous study on liver recipients who did not have a HCV infection. Patients were very likely to be tolerant if they had a certain ratio of two different subgroups of immune cells in their blood. This ratio was also a reliable predictor of tolerance in the new study involving HCV patients.

Dr. Tanja Bauer and Carolina Russo from the Immunmonitoring Platform at the Helmholtz Zentrum München were also involved in the study as cooperation partners. Felix Bohne was awarded a DFG (German Research Foundation) grant for his research work.

Original publication
Felix Bohne, María-Carlota Londoño, Carlos Benítez, Rosa Miquel, Marc Martínez-Llordella, Carolina Russo, Cecilia Ortiz, Eliano Bonaccorsi-Riani, Christian Brander, Tanja Bauer, Ulrike Protzer, Elmar Jaeckel, Richard Taubert, Xavier Forns, Miquel Navasa, Marina Berenguer, Antoni Rimola, Juan-José Lozano, und Alberto Sánchez-Fueyo, HCV-induced immune responses influence the development of operational tolerance following liver transplantation in humans, Science Translational Medicine, 2014.
DOI: 10.1126/scitranslmed.3008793

Prof. Dr. Ulrike Protzer
Technische Universität München / Helmholtz Zentrum München
Institute of Virology
Phone: +49 89 4140 - 6821

Corporate Communications Center

Technical University of Munich Dr. Vera Siegler

Article at

Percy Knolle, Professor für Molekulare Immunologie an der TUM, untersucht die Ursachen des Leberversagens. (Bild: A. Heddergott / TUM)

Liver failure caused by attack on blood vessel cells

In severe cases, a viral hepatitis infection can result in liver failure. A team from the Technical University of Munich (TUM) has now discovered how this occurs: by immune cells attacking cells in the vascular system,...

Das wissenschaftliche Team der Zika-Virus Studie (von links nach rechts): Pietro Scaturro, Prof. Andreas Pichlmair und Dr. Alexey Stukalov. (Bild: A. Eckert / TUM)

Zika virus proteins inhibit brain development

In healthy individuals, the Zika virus causes flu-like symptoms. If a pregnant woman becomes infected, the unborn child can suffer from severe brain abnormalities as a result of mechanisms that have not yet been explained....

Eine therapeutische Imfpung gegen Hepatitis B könnte weltweit Millionen Menschen helfen. (Bild: tommyS /

Treatment for chronic viral infections

Around 260 million people worldwide suffer from chronic Hepatitis B, which is currently incurable. A team from the Technical University of Munich (TUM) and the Helmholtz Zentrum München has developed a therapeutic vaccine...

Prof. Percy Knolle (Mitte) und sein Team im Institut für Molekulare Immunologie / Experimentelle Onkologie.

“Master switch” for chronic infections

Certain viral diseases have a tendency to become chronic – HIV being a notable example. The patient’s immune response is simply not effective enough to eliminate the virus permanently. Researchers at the University of Bonn...

Akram Abdellatif, Prof. Ulrike Protzer und Hanaa Gaber (von links nach rechts) haben gemeinsam die ISS Research Competition gewonnen. (Bild: M. Stobrawe / MRI)

Hepatitis C virus proteins in space

Two Egyptian researchers at Technische Universität München (TUM) have won the “International Space Station (ISS) Research Competition” in the US with their project Egypt Against Hepatitis C Virus (EGAHEP). As their prize,...

Die Abbildung zeigt eine Fluoreszenzaufnahme von Virus-DNA-Rad50-Card9-Komplexen (gelb) im Zytoplasma (Transmissionsbild) einer Zelle. Nach Infektion der Zelle mit einem DNA-Virus markieren die Wissenschaftler die einzelnen Moleküle, die sie in der Zelle beobachten möchten, mit unterschiedlichen fluoreszierenden Farbstoffen. In blau/magenta leuchtet die DNA, in grün Rad50 und in rot Card9.  (Bild: A. Rottach / LMU)

Starting signal for antiviral defense

Cells have to protect themselves: against damage in their genetic material for one thing, but also against attack from the outside, by viruses for example. They do this by using different mechanisms: special proteins search...

Prof. Ulrike Protzer (im Bild) und Prof. Mathias Heikenwälder konnten die virale DNA in Leberzellen zerstören. (Foto: TUM)

Attack on hepatitis B virus DNA

Scientists from the Technische Universität München and the Helmholtz Zentrum München have discovered how the viral DNA of the hepatitis B virus (HBV) can be degraded in the cell nucleus of liver cells, consequently allowing...

In Kokon-artigen Strukturen in der Leber erfolgt die Expansion von T Zellen (grün). Monozyten (rot), unterstützen die T Zell Expansion.

New Immunotherapy Approach to Treat Chronic Infections

A team of scientists from the Technische Universität München, Helmholtz Zentrum München and University of Bonn has deciphered a mechanism that in the future may enable therapeutic vaccination against chronic infections....